Department of Surgery, University of Washington School of Medicine, Seattle, WA.
Division of Cardiac Surgery, Seattle Children's Hospital, Seattle, WA; Department of Surgery, University of Washington School of Medicine, Seattle, WA.
Semin Perinatol. 2014 Mar;38(2):97-103. doi: 10.1053/j.semperi.2013.11.006.
Extracorporeal life support is an important therapy for neonates with life-threatening cardiopulmonary failure. Utilization of extracorporeal life support in neonates with congenital heart disease has increased dramatically during the past three decades. Despite increased usage, overall survival in these patients has changed very little and extracorporeal life support-related morbidity, including bleeding, neurologic injury, and renal failure, remains a major problem. Although survival is lower and neurologic complications are higher in premature infants than term infants, cardiac extracorporeal life support including extracorporeal cardiopulmonary resuscitation is effective in preventing death in many of these high-risk patients. Miniaturized ventricular assist devices and compact integrated extracorporeal life support systems are being developed to provide additional therapeutic options for neonates.
体外生命支持是治疗危及生命的心肺衰竭新生儿的重要方法。在过去的三十年中,体外生命支持在患有先天性心脏病的新生儿中的应用急剧增加。尽管使用量增加,但这些患者的总体生存率几乎没有变化,体外生命支持相关的发病率,包括出血、神经损伤和肾衰竭,仍然是一个主要问题。尽管早产儿的生存率较低,神经并发症较高,但体外心肺复苏等心脏体外生命支持在许多高危患者中可有效预防死亡。正在开发微型心室辅助装置和紧凑集成的体外生命支持系统,为新生儿提供更多的治疗选择。